What success looks like after stopping Mounjaro — and what the evidence actually says

What the SURMOUNT trial data tell us about stopping tirzepatide

The clearest evidence on discontinuation comes from the wider tirzepatide clinical programme. In SURMOUNT-1, adults without diabetes lost an average of around 20–21% of their body weight over 72 weeks on 15 mg tirzepatide, as published in the New England Journal of Medicine. The follow-up question (what happens when the medicine stops) was addressed in the SURMOUNT-4 extension. Participants who had already completed a 36-week open-label lead-in on tirzepatide were then randomised to either continue or switch to placebo. Those who continued lost a further 5.5% on average over the following 52 weeks; those who switched to placebo regained roughly half of the weight they had lost during the lead-in period.

That figure deserves some nuance. It is an average across a clinical-trial population with standardised support. Some participants maintained the majority of their loss; others regained more quickly. The key variable the trial did not fully isolate is what each person did with their eating and activity habits after stopping, which, in practice, matters a great deal.

Worth doing now: pull up the NHS tirzepatide information page and read the section on stopping treatment. It takes under a minute and sets out the patient-level context clearly.

Why some people maintain their losses better than others

Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) that influence appetite, fullness and gastric emptying. When the medicine is stopped, those signals revert to baseline relatively quickly. For people who have spent treatment time building new eating patterns, portion awareness and consistent exercise, that reversion is cushioned by habit. For people who relied primarily on the suppressed appetite to carry them, the return of hunger can feel abrupt.

This is not a failure of willpower. Appetite regulation is largely biological, and tirzepatide changes the biology temporarily. The people who fare best after stopping tend to have used the lower-appetite window to rebuild what they eat, rather than just how much. High-protein intake, fibre, strength-based activity and regular meal timing all appear in the clinical literature as supportive factors, but personal plans are best agreed with your prescriber or a dietitian rather than drawn from generalisations.

The practical guide on what happens after stopping Mounjaro covers the physiological timeline in more detail for anyone approaching that conversation.

How success after stopping actually gets defined, and why it varies

"Success" in this context means different things to different people. In clinical trials, it is typically defined as maintaining a threshold percentage of the weight lost. In real life, success might be a stable weight within a range, improved metabolic markers, better mobility or simply feeling in control of food rather than controlled by it. Accounts from people who have used tirzepatide reflect this range, weight on the scale is rarely the only measure that matters to them a year later.

NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has been achieved after six months at the highest tolerated dose, continuing treatment warrants review. The converse also applies: people who have achieved substantial, stable loss with good lifestyle integration may, in discussion with their prescriber, choose to step down or stop, with a clear plan for what follows. That plan, and the monitoring around it, is where clinical oversight earns its place. Reading through what patients across the UK have said about their Mounjaro results can also give useful real-world context when weighing up a continuation decision, alongside understanding the cost context of long-term Mounjaro treatment.

What the experiences shared by people who have come off Mounjaro tend to have in common is a period of deliberate preparation, working with a prescriber on timing, not stopping at a random point, and having support structures in place before the medicine ends.

The role of clinical review in planning discontinuation

Mounjaro is a prescription-only medicine. Stopping it is not simply a matter of putting the pen down; it requires the same clinical consideration as starting. A prescriber needs to know your current weight, the trajectory over recent months, any conditions that prompted treatment in the first place, and what support will be in place afterwards. That review also catches people for whom stopping is premature, weight that feels stable at week 72 can begin to shift within months if the physiological cues return and the environmental context hasn't changed.

At nume, every repeat order is clinically reviewed, not auto-renewed. That same process applies when a patient raises discontinuation: it becomes a conversation with a prescriber, not a unilateral decision made through an app. If you are considering whether Mounjaro could be the right long-term fit for your situation or are approaching the point of stopping, a consultation with our prescribers is the right starting point. The clinical team page gives a clearer picture of who reviews your case.